Background
Housey Pharmaceuticals owned patents covering a method of screening for substances that specifically inhibit or activate particular proteins — a technique central to drug discovery research. The patented method involved creating cell lines with elevated protein production, then exposing the cells to candidate drug substances to determine whether those substances inhibited or activated the target protein. Identifying a substance with the right inhibitory or activatory profile is a critical early step in pharmaceutical research: it allows drug developers to focus their efforts on promising compound leads rather than testing every possible molecule indiscriminately.
When Bayer AG used similar screening methods in its overseas laboratories to identify drug leads, and then imported the resulting drug products into the United States, Housey sued for infringement under 35 U.S.C. § 271(g). That statute extends U.S. patent protection to products that are manufactured abroad by a process that would infringe a U.S. patent if practiced domestically. The statute was enacted in 1988 to address the problem of manufacturers evading U.S. process patents by moving their manufacturing operations overseas. Housey argued that Bayer’s drugs were “made” by its patented screening process and therefore could not be imported without license. Bayer sought a declaratory judgment of non-infringement and the district court dismissed Housey’s claims. Housey appealed.
The Court’s Holding
The Federal Circuit affirmed. Writing for the court, Judge Dyk held that § 271(g) has two important limits that Housey’s claims could not satisfy.
First, the court held that § 271(g) applies only to physical goods that were manufactured — it does not extend to information generated by using the patented process. The production of information is outside the scope of processes of manufacture as the term is used in § 271(g). The screening method identified chemical compounds worth pursuing, but it did not manufacture those compounds or any physical product. What it produced was knowledge — information about which molecules had the desired biological properties. Information is not a manufactured product, and therefore importing information obtained by practicing the patented process overseas does not infringe under § 271(g).
Second, the court held that a product must be made “by” the patented process in a direct sense — the process must actually be used in manufacturing the product, not merely as a predicate step that identifies what product to later manufacture. Bayer’s screening method identified which drug compounds to pursue; separate manufacturing processes then actually synthesized and produced those drug compounds. The screening process was a precursor to manufacturing, not manufacturing itself. Because the patented process did not directly make the imported drugs — it only identified the drug leads — the final products were not “products made by” the patented process within the meaning of § 271(g).
Key Takeaways
- 35 U.S.C. § 271(g) covers only physical products actually manufactured by a patented process — it does not extend to information, data, or research results generated by using the patented process overseas.
- A drug identified through a patented screening method is not “made by” that method within the meaning of § 271(g) if the patented process merely identified the drug lead without itself manufacturing the drug molecule.
- Section 271(g) requires direct causation — the patented process must be used directly in manufacturing the imported product, not merely as an upstream step that informs or leads to later manufacturing.
- Pharmaceutical companies conducting drug discovery research abroad using patented screening processes do not necessarily expose themselves to § 271(g) liability for importing the resulting drug products, because the screening identifies what to make, while separate processes actually make it.
- This decision significantly limited the reach of § 271(g) for biotechnology and pharmaceutical research method patents, distinguishing research tools that generate information from manufacturing processes that create physical products.
Why It Matters
Bayer v. Housey is an important case for pharmaceutical and biotechnology patent law because it defines the outer limits of § 271(g) — the statute that extends process patent protection to imported products. High-throughput screening, combinatorial chemistry, and other drug discovery research methods are often patented in the United States. If § 271(g) extended to products merely identified (but not manufactured) by these research methods, it could dramatically restrict pharmaceutical companies’ ability to conduct drug discovery research abroad and import the resulting drug candidates for further development.
By holding that § 271(g) reaches only physical manufacturing processes — not information-generating research processes — the Federal Circuit preserved significant freedom for pharmaceutical research conducted overseas. The distinction between generating information about a product and physically manufacturing it is fundamental: a patented drug screening test tells you which molecule to make, but a separate synthesis process makes it. Only the manufacturing process, if patented, would give rise to § 271(g) liability. This framework has lasting significance as drug discovery has become increasingly data-intensive and as the boundary between research methods and manufacturing steps has remained contested in pharmaceutical patent litigation.